Sulodeksid
Prijeđi na navigaciju
Prijeđi na pretragu
Klinički podaci | |
---|---|
AHFS/Drugs.com | Monografija |
Identifikatori | |
CAS broj | 57821-29-1 |
ATC kod | B01AB11 |
DrugBank | DB06271 |
Hemijski podaci | |
Formula | ? |
Farmakokinetički podaci | |
Poluvreme eliminacije | 11,7 h |
Farmakoinformacioni podaci | |
Trudnoća | ? |
Pravni status |
Sulodeksid je visoko prečišćena smeša glikozaminoglikanskih jedinjenja heparina niske molekularske težine (80%) i dermatan sulfata (20%).[1][2][3][4]
Reference[uredi | uredi kod]
- ↑ Cosmi B, Cini M, Legnani C, Pancani C, Calanni F, Coccheri S: Additive thrombin inhibition by fast moving heparin and dermatan sulfate explains the anticoagulant effect of sulodexide, a natural mixture of glycosaminoglycans. Thromb Res. 2003 Mar 15;109(5-6):333-9. PMID 12818259
- ↑ Harenberg J: Review of pharmacodynamics, pharmacokinetics, and therapeutic properties of sulodexide. Med Res Rev. 1998 Jan;18(1):1-20. PMID 9436179
- ↑ Knox C, Law V, Jewison T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS (2011). „DrugBank 3.0: a comprehensive resource for omics research on drugs”. Nucleic Acids Res. 39 (Database issue): D1035-41. DOI:10.1093/nar/gkq1126. PMC 3013709. PMID 21059682.
- ↑ David S. Wishart, Craig Knox, An Chi Guo, Dean Cheng, Savita Shrivastava, Dan Tzur, Bijaya Gautam, and Murtaza Hassanali (2008). „DrugBank: a knowledgebase for drugs, drug actions and drug targets”. Nucleic Acids Res 36 (Database issue): D901-6. DOI:10.1093/nar/gkm958. PMC 2238889. PMID 18048412.
Literatura[uredi | uredi kod]
- Hardman JG, Limbird LE, Gilman AG. (2001). Goodman & Gilman's The Pharmacological Basis of Therapeutics (10 izd.). New York: McGraw-Hill. DOI:10.1036/0071422803. ISBN 0-07-135469-7.
- Thomas L. Lemke, David A. Williams, ur. (2007). Foye's Principles of Medicinal Chemistry (6 izd.). Baltimore: Lippincott Willams & Wilkins. ISBN 0-7817-6879-9.